Business Wire

1GLOBAL Launches Verint Communications Analytics to Enhance Cloud Compliance for Financial and Regulated Industries

20.5.2026 16:00:00 EEST | Business Wire | Press release

Share

1GLOBAL, a pioneer in global telecommunications solutions, today announced its launch of Verint® Communications Analytics, a key offering within Verint Financial Compliance (VFC) providing mobile call transcription and analytics capabilities. Verint Communications Analytics has been designed to help financial institutions and regulated organizations accelerate productivity when monitoring voice calls (including mobile), identifying behavioral patterns, querying data intentionally by topic, risks, keywords or sentiment, identifying misuse and reducing regulatory risk.

Verint Communications Analytics is seamlessly integrated into 1GLOBAL’s mobile platform across 10 international markets. It enables cloud compliance customers to achieve faster and more efficient results via transcription and various analytics.

Transforming Raw Data into Actionable and Valuable Intelligence

As regulatory scrutiny intensifies, financial firms face growing pressure to monitor communications more comprehensively, yet many still rely on fragmented recording tools and a time-consuming manual review process.

1GLOBAL’s use of Verint Communications Analytics fundamentally addresses this challenge by transforming compliance from a reactive obligation into a proactive intelligence function.

The 1GLOBAL Cloud Compliance Platform records all mobile calls and SMS and securely transfers them to Verint Communications Analytics for automated transcription, summarization, sentiment analysis, and multilingual topic detection – translating from 30+ languages into English with near real-time processing.

This allows compliance teams working in financial institutions and regulated industries to identify risks faster and investigate potential issues in days rather than weeks, completely securely.

1GLOBAL’s entire architecture is deployed in multiple regions, including EMEA (Europe, Middle East and Africa) and North America, ensuring that call media is always processed locally within the customer’s regulatory jurisdiction and never transferred across regions. This is why 1GLOBAL Compliance is trusted by regulated financial institutions, including eight of the world’s top ten investment banks.

Siobhan Thompson, Head of Sales, 1GLOBAL Compliance, said: “In today’s regulatory environment, firms need confidence that business communications are being captured accurately and reviewed efficiently. By combining Verint Communications Analytics with our global mobile recording capabilities, we help compliance teams identify potential risks faster, reduce operational burden, and strengthen oversight across regulated communications.”

John Bourne, SVP Global Channels and Alliances, Verint, said: “Extending Verint Communications Analytics to 1GLOBAL’s mobile network marks an important step in how regulated firms can apply AI to voice data at a global scale. Together we are equipping compliance and risk teams with a unified view across mobile communications, helping them move from sampling and spot checks to continuous, intelligent oversight.”

About 1GLOBAL: Leading Digital Transformation in Telecommunications

1GLOBAL is a technology-driven global mobile communications provider dedicated to empowering enterprises worldwide to unlock the full growth potential of mobile connectivity. With a best-in-class telecom technology platform, a comprehensive suite of globally viable regulatory licenses, and privileged access to the telecom wholesale market, 1GLOBAL is uniquely positioned to deliver seamless mobile connectivity solutions. Serving the world’s leading banks, corporations, and digital-first businesses—including neo-banks, travel companies, and retail groups—1GLOBAL connects over 60 million devices globally.

In 2025, 1GLOBAL continued to grow profitably, generating revenue of USD 203 million and a profit of USD 26 million. The year was characterized by strong demand for the 1G Connect Travel™ offering, the expansion of enterprise and compliance solutions, and continued investment in eSIM technology. Going forward, 1GLOBAL will focus on expanding national connectivity, extending its MVNO footprint and scaling its technology platform to continue delivering sustainable, profitable growth. Established in 2022 by experienced tech founders and entrepreneurs Hakan Koç and Pyrros Koussios, 1GLOBAL is a European technology leader driving digital transformation in the global telecommunications market. It operates as a fully regulated Mobile Virtual Network Operator (“MVNO”) in 12 countries and as a regulated telecommunications operator in an additional 28 countries. Headquartered in the Netherlands, with world-class R&D hubs in Lisbon, Berlin, and São Paulo, 1GLOBAL employs close to 500 experts across 15 countries.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260520420998/en/

Contacts

Contact 1GLOBAL
1GLOBAL Communications Email: press@1global.com
www.1global.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.1global.com
&esheet=54539095&newsitemid=20260520420998&lan=en-US&anchor=www.1global.com&inde
x=1&md5=4f8a2d9edff4957a5fabff8f3b06c60e

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye